Current PHP version: 5.5.38
BSI licenses and sells it’s diagnostic candidate products. The pipeline includes lung-, breast and colon cancer and diabetes diagnostics.  
  • Lung Cancer
For lung cancer, the average 5 year survival rate is a dismal 15%. This is largely due to the fact that the disease is detected very late. With early detection and treatment, the 5 year survival rate jumps to over 50%. The first version of BSI’s lung cancer diagnostics mAb panel of BSI was purchased  by Roche Diagnostics GmbH in 17/04/2012. A novel LC assay was licensed to Randox Ltd. recently (http://www.prweb.com/releases/2015/11/prweb13096783.htm).
  • Breast Cancer
Despite recent developments in timely detection and management of Breast Cancer (BC), it persists to be a common and significant health problem worldwide. BC is the most common cancer among women and second leading cause of death. In the US alone, an estimated 230,000 new cases of invasive breast cancer are diagnosed each year, and approximately 40,000 deaths occur from breast cancer each year. At the same time, if diagnosed in a localized stage with early detection, the 5-year survival rate is 99%! Current detection of BC relies heavily on radiologic imaging (mammography) and subsequent biopsy.
  • Colon Cancer
Early detection of Colon Cancer (CC) is crucial to increase survival rates because more than 90% of those diagnosed with early-stage CC live 5 or more years after treatment, and screening procedures are key to an earlier diagnosis. Among others, several different procedures and tests have been used for screening CC, including colonoscopy, the faecal occult blood test (FOBT). However, accuracy of faecal tests is low. Evidence strongly suggests that screening for CC has resulted in reduced mortality and morbidity of the disease, however, in western countries only about 40-65% of those older than 50 years of age have undergone any form of CC screening in the recent past.